Adjuvant Chemotherapy for Adenocarcinoma of the Lung -- Is the Standard of Care Ready for Change?

doi:10.1056/NEJMe048035

Volume 350:1777-1779		April 22, 2004		Number 17

Adjuvant Chemotherapy for Adenocarcinoma of the Lung — Is the Standard of Care Ready for Change?

Robert B. Diasio, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Full Text

PDF

PDA Full Text

Purchase this article

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

Related Article
by Kato, H.

PubMed Citation

The treatment for stage I non–small-cell lung cancer,regardless of cell type, is wide surgical resection (lobectomyor pneumonectomy) of the involved area.¹ Although the propensityof non–small-cell lung cancer to metastasize early iswell recognized, there is no convincing evidence that postoperativeradiotherapy or adjuvant chemotherapy improves survival in stageI disease. As a result, guidelines in the United States do notrecommend any adjuvant treatment outside of the clinical-trialsetting.¹ Many of the relatively small studies that have suggestedthat chemotherapy can improve survival in non–small-celllung cancer²^,³ used the same agents that have proved usefulin advanced . . . [Full Text of this Article]

Source Information

From the Departments of Medicine and Pharmacology and Toxicology and the Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham.